The investigational endoscopic procedure may help patients maintain weight loss or lose more weight 3 months after GLP-1 receptor agonist therapy discontinuation.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Van Baar and colleagues’ study comprised 16 patients ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An investigative ...

HealthDay News — Single-procedure duodenal mucosal resurfacing (DMR) is effective for reducing glycated hemoglobin (HbA1c) in patients with type 2 diabetes, according to a study published online in ...

The FDA has granted breakthrough device designation to Fractyl Laboratories Inc. for Revita DMR, a duodenal mucosal resurfacing treatment for patients with type 2 diabetes. The company recently ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Laboratories Inc. (Fractyl) today announced positive results from the Revita-2 trial evaluating Revita DMR (duodenal mucosal resurfacing) for the treatment ...

Improving metabolic disorders without major changes in diet and exercise is typically seen as impossible, unless bariatric surgery is involved. But that’s precisely what Fractyl Laboratories Inc. aims ...

Patients with poorly controlled type 2 diabetes who underwent a novel, minimally invasive, endoscopic procedure called Revita ® duodenal mucosal resurfacing (DMR) had significantly improved blood ...

WASHINGTON--Patients with poorly controlled type 2 diabetes who underwent a novel, minimally invasive, endoscopic procedure called Revita® duodenal mucosal resurfacing (DMR) had significantly improved ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA granted breakthrough device designation for a ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today ...

BOSTON — An ablative procedure intended to promote regrowth of duodenal mucosa was safe and had disease-modifying metabolic effects in a randomized study including patients with type 2 diabetes, ...